2seventy bio Reports First Quarter Financial Results and Recent Operational Progress U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets Company on Track to Focus Exclusively on Development and Commercialization of Abecma with Streamlined Cost Structure Abecma generated $52 million U.S. commercial revenue in the first quarter of 2024 Ended quarter wit ...